Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction.
In 15 patients with chronic heart failure of ischemic origin who were not previously treated with angiotensin-converting enzyme inhibitors, platelets exhibited hyperaggregability and impaired responsiveness to the antiaggregatory and cyclic guanosine monophosphate-stimulatory effects of nitric oxide donor sodium nitroprusside compared with normal subjects; this was paralleled by increased blood levels of superoxide radicals. Treatment with perindopril for 4 days significantly improved platelet responses to sodium nitroprusside; there was also a trend toward a decrease in superoxide radical levels.
Chirkov
Yuliy Y
YY
Cardiology Unit, The Queen Elizabeth Hospital, Department of Medicine, The University of Adelaide, Woodville 5011, Adelaide, Southern Australia, Australia.
Holmes
Andrew S
AS
Martelli
Jason D
JD
Horowitz
John D
JD
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000494:pharmacology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D020913:Perindopril / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests; D013481:Superoxides / Q000097:blood; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000150:complications*
D000806:Angiotensin-Converting Enzyme Inhibitors; D020030:Nitric Oxide Donors; D013481:Superoxides; D009599:Nitroprusside; D009569:Nitric Oxide; D006152:Cyclic GMP; D020913:Perindopril